Keros Therapeutics, Inc.
KROS Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$11.43
KIRA · Stoqly’s AI analyst, in plain words
- Keros Therapeutics, Inc. had $244M of revenue in fiscal 2025.
- Its operating margin was 27.7%: of every 100 in sales, about 28 is left after running the business.
- Keros Therapeutics, Inc. made $87.0M of net profit in fiscal 2025.
- Free cash flow was $106M in fiscal 2025, 43.4% of revenue.
- Keros Therapeutics, Inc. returned $375M to shareholders in fiscal 2025, 354% of free cash flow. The diluted share count rose 1.1%.
Market cap
$226M
P/E
—
Revenue
$244M
Net income
$87.0M
Free cash flow
$106M
Operating margin
27.7%
Keros Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
35.7%
Yes. It keeps 35.7% of every sale as profit.
Does profit turn into cash?
43.4%
Yes. 43.4% of sales ends up as free cash.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Keros Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Keros Therapeutics, Inc.
- CIK
- 0001664710
Keros Therapeutics, Inc. · KROS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $20.1M | $0.0M | $0.2M | $0.0M | $244M |
| Revenue growth | — | −100.0% | — | −100.0% | — |
| Operating margin | −280.5% | — | −112,543.7% | — | 27.7% |
| Net income | −$58.7M | −$105M | −$153M | −$187M | $87.0M |
| Net margin | −292.3% | — | −101,319.2% | — | 35.7% |
| Diluted EPS | −$2.52 | −$4.15 | −$5.20 | −$5.00 | $2.30 |
| Cash | |||||
| Cash from operations | −$62.1M | −$70.1M | −$125M | −$161M | $108M |
| Capital expenditure | $1.0M | $1.2M | $2.5M | $1.9M | $1.6M |
| Free cash flow | −$63.2M | −$71.3M | −$127M | −$163M | $106M |
| FCF margin | −314.3% | — | −84,087.4% | — | 43.4% |
| Share buybacks | — | — | — | $0.0M | $375M |
| Share count change | 50.5% | 8.2% | 16.7% | 27.1% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $230M | $279M | $331M | $560M | $287M |
| Shareholders' equity | $243M | $277M | $332M | $572M | $303M |
| Current ratio | 21.2x | 17.3x | 14.2x | 21.5x | 15.5x |
| Interest coverage | −14,093.3x | −114,790.0x | — | — | — |
| Returns and quality | |||||
| Return on equity | −23.3% | −40.2% | −50.2% | −41.5% | 19.9% |
| Return on tangible equity | −24.2% | −37.7% | −46.1% | −32.8% | 28.7% |
| Piotroski F-score | 1 | 1 | 2 | 3 | 5 |
| Altman Z'' | 24.2 | 10.7 | 8.5 | 14.2 | 11.5 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.5M
9 insiders
Of sales under plans
18%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Keros Therapeutics, Inc. · KROS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.43 a share, the company is worth $226M.
Source: SEC EDGAR XBRL filings (CIK 0001664710). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.